{"id":"https://openalex.org/W20749119","doi":"https://doi.org/10.1007/978-3-322-87010-0_12","title":"Nischenstrategie versus Generalistentum: Wo liegt die Zukunft f\u00fcr die Pharma-Industrie","display_name":"Nischenstrategie versus Generalistentum: Wo liegt die Zukunft f\u00fcr die Pharma-Industrie","publication_year":2003,"publication_date":"2003-01-01","ids":{"openalex":"https://openalex.org/W20749119","doi":"https://doi.org/10.1007/978-3-322-87010-0_12","mag":"20749119"},"language":"de","primary_location":{"id":"doi:10.1007/978-3-322-87010-0_12","doi":"https://doi.org/10.1007/978-3-322-87010-0_12","is_oa":false,"landing_page_url":"https://doi.org/10.1007/978-3-322-87010-0_12","pdf_url":null,"source":{"id":"https://openalex.org/S4306463308","display_name":"Gabler Verlag eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Strategien f\u00fcr das Pharma-Management","raw_type":"book-chapter"},"volume":{"id":"https://openalex.org/W2485881684","display_name":"Strategien f\u00fcr das Pharma-Management"},"type":"book-chapter","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041187591","display_name":"Andreas Fibig","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andreas Fibig","raw_affiliation_strings":["Gesch\u00e4ftsf\u00fchrer,\n        Pharmacia GmbH, Erlangen, Deutschland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gesch\u00e4ftsf\u00fchrer,\n        Pharmacia GmbH, Erlangen, Deutschland","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044338409","display_name":"Hans H\u00fctt","orcid":"https://orcid.org/0000-0003-1171-4415","observed_orcids":["https://orcid.org/0000-0003-1171-4415"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hans Joachim Hutt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.00583009,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"197","last_page":"210"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12123","display_name":"Financial Analysis and Corporate Governance","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1402","display_name":"Accounting"},"field":{"id":"https://openalex.org/fields/14","display_name":"Business, Management and Accounting"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11649","display_name":"Pharmaceutical industry and healthcare","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pharmaceutical-industry","display_name":"pharmaceutical industry","score":0.9879999756813049},{"id":"https://openalex.org/keywords/niche-strategy","display_name":"niche strategy","score":0.9570000171661377},{"id":"https://openalex.org/keywords/generic-drugs","display_name":"generic drugs","score":0.42500001192092896},{"id":"https://openalex.org/keywords/pharmaceutical-policy","display_name":"pharmaceutical policy","score":0.44600000977516174},{"id":"https://openalex.org/keywords/drug-approval","display_name":"drug approval","score":0.5059999823570251},{"id":"https://openalex.org/keywords/research-pipeline","display_name":"research pipeline","score":0.6489999890327454},{"id":"https://openalex.org/keywords/innovation","display_name":"innovation","score":0.4090000092983246},{"id":"https://openalex.org/keywords/profitability","display_name":"profitability","score":0.49900001287460327},{"id":"https://openalex.org/keywords/stock-performance","display_name":"stock performance","score":0.5789999961853027}],"concepts":[{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.5152566432952881},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.47080695629119873},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.05473434925079346}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1007/978-3-322-87010-0_12","doi":"https://doi.org/10.1007/978-3-322-87010-0_12","is_oa":false,"landing_page_url":"https://doi.org/10.1007/978-3-322-87010-0_12","pdf_url":null,"source":{"id":"https://openalex.org/S4306463308","display_name":"Gabler Verlag eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Strategien f\u00fcr das Pharma-Management","raw_type":"book-chapter"}],"best_oa_location":null,"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2090112025","https://openalex.org/W146135981","https://openalex.org/W2422496454","https://openalex.org/W499214087","https://openalex.org/W2321995530","https://openalex.org/W2045185355","https://openalex.org/W4404284581","https://openalex.org/W4248249837","https://openalex.org/W4285153148","https://openalex.org/W158796497"],"abstract_inverted_index":{"Nach":[0],"einer":[1],"Phase":[2],"deutlicher":[3],"Profitabilit\u00e4tssteigerungen":[4],"ist":[5],"auch":[6,19],"die":[7,14,22,56],"\u201eWachstumsbranche\u201c":[8],"Arzneimittelindustrie":[9],"zahlreichen":[10],"neuen":[11],"Herausforderungen":[12],"ausgesetzt,":[13],"in":[15,65,88],"den":[16,60,66,73],"n\u00e4chsten":[17],"Jahren":[18],"Auswirkungen":[20],"auf":[21],"Kurs/Gewinn-Verh\u00e4ltnisse":[23],"haben":[24,28],"werden.":[25],"Die":[26,75],"Pharmaunternehmen":[27],"bisher":[29,91],"mit":[30],"zweistelligen":[31],"Umsatzzuwachsraten":[32],"und":[33,38,58,71,83,102],"\u00fcberproportionalen":[34],"EBIT-Wachstum":[35],"gl\u00e4nzen":[36],"k\u00f6nnen,":[37],"alle":[39],"Welt":[40],"hat":[41],"nur":[42],"von":[43],"Blockbustern":[44],"gesprochen.":[45],"Doch":[46],"das":[47],"pharmapolitische":[48],"Umfeld":[49],"ver\u00e4ndert":[50],"sich.":[51],"F\u00fcr":[52],"neue":[53],"Pr\u00e4parate":[54],"steigen":[55],"Launchrisiken,":[57],"aus":[59],"Forschungspipelines":[61],"kommen":[62],"weniger":[63],"Innovationen":[64],"Markt.":[67,74],"Zus\u00e4tzlich":[68],"belasten":[69],"Zulassungsh\u00fcrden":[70],"Erstattungserschwernisse":[72],"gro\u00dfen":[76],"Pharmafirmen":[77],"zeigen":[78],"dabei":[79],"eine":[80],"unterschiedliche":[81],"Performance":[82],"auff\u00e4llig":[84],"ist,":[85],"dass":[86],"\u2014":[87,93],"dieser":[89],"Branche":[90],"un\u00fcblich":[92],"zunehmend":[94],"Gewinnwarnungen":[95],"auftauchen.":[96],"Probleme":[97],"bei":[98],"Zulassungen,":[99],"verstopfte":[100],"Pipelines":[101],"\u201enur\u201c":[103],"einstellige":[104],"Wachstumsraten":[105],"f\u00fchren":[106],"neben":[107],"einem":[108],"ansteigenden":[109],"Generikadruck":[110],"zu":[111],"Kursproblemen.":[112]},"counts_by_year":[],"updated_date":"2026-10-10T09:11:00.788812","created_date":"2016-06-24T00:00:00"}